Advertisement

Role of macrophages in Guillain-Barré syndrome: contributes with the outcome

American Journal of BioMedicine  Volume 2, Issue 8, pages 887-898, August 2014


Robert G. Andrews; Yixin Lin; Limin Lee; Lisa H. Athey; Wei Wang; Xiaobo Chen

Abstract

Guillain-Barré syndrome (GBS) occurs throughout the world with a median annual incidence of 1.3 cases per population of 100 000, with men being more frequently affected than women. GBS is currently divided into the two major subtypes: acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN) and clinically is defined as an acute peripheral neuropathy causing limb weakness that progresses over a time period of days or, at the most, up to 4 weeks. Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus and Mycoplasma pneumonia are commonly identified antecedent pathogens. Strong evidence now exists that axonal subtypes of Guillain-Barré syndrome is caused by antibodies to gangliosides on the axolemma that target macrophages to invade the axon at the node of Ranvier, further, macrophages infiltrate peripheral nerves and may contribute to neural damage in the GBS. This review highlights relevant recent publications, particularly on the outcome of macrophages in Guillain-Barré syndrome.

Kewords: Guillain-Barré syndrome; macrophages; Acute motor axonal neuropathy; Campylobacter jejuni


Limited Access               HTML                 Full Text-PDF                Feedback


References

1. Nachamkin I, Allos BM, Ho T. Campylobacter species and Guillain-Barre syndrome. Clin Microbiol Rev 1998;11: 555–567.  [PubMed]

2. de Jager AE, Sluiter HJ. Clinical signs in severe Guillain-Barre syndrome: analysis of 63 patients. J Neurol Sci 1991; 104: 143–150. [PubMed]

3. Ropper AH. The Guillain-Barre syndrome. N Engl J Med  1992; 326: 1130–1136. [PubMed]

4. Hughes RAC, Cornblath DR. Guillain-Barré syndrome. Lancet 2005; 366: 1653–1666. [PubMed]

5. Kang JH, Sheu JJ, Lin HC. Increased risk of Guillain-Barré syndrome following recent herpes zoster: A population-based study across Taiwan. Clin Infect Dis 2010; 51: 525–530. [PubMed]

6. Wim Ang C, Jacobs BC, Laman JD. The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol 2004; 25: 61–66. [PubMed]

7. Kusunoki S, Kaida K. Antibodies against ganglioside complexes in Guillain-Barré syndromé and related disorders. J Neurochem 2011; 116: 828–832. [PubMed]

8. Boldron J, Caltabiano S, Debono SD, Thompson R, Scammells M, Westover R, Wu Y, Frugier P. Adhesion molecule expression trigger immune-mediated pathology in lupus-nephritis. American Journal of BioMedicine  2013;1(2): 49–57. [Abstract/Full-Text]

9. Gabriel CM, Gregson NA, Hughes RAC. Anti-PMP22 antibodies in patients with inflammatory neuropathy. J Neuroimmunol 2000;104: 139–146. [PubMed]

10. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, et al. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004; 30: 131–156. [PubMed]

11. Marchiori PE, Dos Reis M, Quevedo ME, Callegaro D, Hirata MT, et al. Cerebrospinal fluid and serum antiphospholipid antibodies in multiple sclerosis, Guillain-Barré syndrome and systemic lupus erythematosus. Arq Neuropsiquiatr 1990; 48: 465–468. [PubMed]

12. Nishino S, Kanbayashi T, Fujiki N, Uchino M, Ripley B, et al. CSF hypocretin levels in Guillain-Barré syndrome and other inflammatory neuropathies. Neurology 2003; 61: 823–825. [PubMed]

13. Chiang HL, Lyu RK, Tseng MY, Chang KH, Chang HS, et al. Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barré syndrome and other neurological disorders. Clin Chim Acta 2009; 405: 143–147. [PubMed]

14. Sainaghi PP, Collimedaglia L, Alciato F, Leone MA, Naldi P, et al. The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barré syndrome from chronic inflammatory demyelinating polyneuropathy. Cytokine 2010; 51: 138–143. [PubMed]

15. Harness J, McCombe PA. Increased levels of activated T-cells and reduced levels of CD4/CD25+ cells in peripheral blood of Guillain-Barré syndrome patients compared to controls. J Clin Neurosci 2008; 15: 1031–1035. [PubMed]

16. Sheu JY, Kulhanek DJ, Eckenstein FP. Differential patterns of ERK and STAT3 phosphorylation after sciatic nerve transection in the rat. Exp Neurol 2000; 166: 392–402. [PubMed]

17. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27: SupplS21–24. [PubMed]

18. Kang JH, Ho JD, Chen YH, Lin HC. Increased risk of stroke after a herpes zoster attack: a population-based follow-up study. Stroke 2009;40(11):3443-3448. [Abstract/FREE Full Text]

19. Ormerod IE, Cockerell OC. Guillain-Barrésyndrome after herpes zoster infection: a report of 2 cases. Eur Neurol 1993; 33(2):156-158. [PubMed]

20. Pavone P, Maccarrone F, Sorge A, Piccolo G, Greco F, Caruso P, Sorge G. Guillain-Barré syndrome after varicella zoster virus infections. A case report. Minerva Pediatr. 2002; 54(3): 259-62. [PubMed]

21. Yoshikawa T, Suzuki K, Suga S, Miyata E, Yamamoto H, Hosokawa T, Kumagai T, Asano Y. Immune response to gangliosides in a case of Guillain-Barré syndrome after varicella. Arch Dis Child 2000 ;83(2):172-3. [PubMed]

22. Sugiyama N, Hamano S, Koga M. High-dose intravenous immunoglobulin therapy in a child case of Bickerstaff's brainstem encephalitis. No To Hattatsu 2003 ;35(4): 327-30. [PubMed]

23. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Clinical correlates of serum anti-GT1a IgG antibodies. J Neurol Sci 2004 ;219(1-2):139-45. [PubMed]

24. Odaka M, Yuki N, Yamada M, Koga M, Takemi T, Hirata K, Kuwabara S. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain. 2003 ;126(Pt 10): 2279-90. [PubMed]

25. Nyati KK, Prasad KN, Verma A, Paliwal VK. Correlation of matrix metalloproteinases-2 and -9 with proinflammatory cytokines in Guillain-Barré syndrome. J Neurosci Res 2010; 88: 3540–3546. [PubMed]

26. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27: SupplS21–24. [PubMed]

27. Grotenhuis N, Vd Toom HF, Kops N, Bayon Y, Deerenberg EB, Mulder IM, van Osch GJ, Lange JF, Bastiaansen-Jenniskens YM. In vitro model to study the biomaterial-dependent reaction of macrophages in an inflammatory environment. Br J Surg 2014 ;101(8): 983-92. [PubMed]

28. Greenhalgh AD, David S. Differences in the phagocytic response of microglia and peripheral macrophages after spinal cord injury and its effects on cell death. J Neurosci 2014; 34(18): 6316-22. [PubMed]

29. Wu X, Wu W2, Wang Z, Shen D, Pan W, Wang Y, Wu L, Wu X, Feng J, Liu K, Zhu J, Zhang HL. More Severe Manifestations and Poorer Short-Term Prognosis of Ganglioside-Associated Guillain-Barré Syndrome in Northeast China. PLoS One. 2014 ;9(8):e104074. [PubMed]

30. Komagamine T, Yuki N. Ganglioside mimicry as a cause of Guillain-Barré syndrome. CNS Neurol Disord Drug Targets 2006;5(4):391-400. [PubMed]

31. Inés González-Suárez, Irene Sanz-Gallego, Francisco Rodríguez de Rivera, Javier Arp. Guillain-Barré Syndrome: Natural history and prognostic factors: a retrospective review of 106 cases. BMC Neurology 2013; 13:95. [Abstract/Full-text]

American Journal of Biomedicine © 2017 Frontier Theme
%d bloggers like this: